Skip to content

The effects of melatonin in the treatment of delirium- a double blind, randomized, placebo-controlled trial.

The effects of melatonin in the treatment of delirium- a double blind, randomized, placebo-controlled trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON21861
Enrollment
200
Registered
2009-02-04
Start date
2009-05-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

delirium, medically-ill, elderly patients. delier, interne-aandoeningen, oudere patienten.

Interventions

patients receive anti-psychotics and melatonin or antipsychotics and placebo.

Sponsors

Academic Medical Center Amsterdam
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 65 years or older; 2. Acute hospital admission at medical ward; 3. Patients diagnosed with delirium for which anti-psychotic therapy is needed; 4. Patients must be willing and medically able to receive therapy according to the protocol for the duration of the study; 5. Written informed consent must be obtained.

Exclusion criteria

Exclusion criteria: 1. Patients on medication that can’t speak or understand Dutch; 2. Patients diagnosed with delirium who have received anti-psychotics longer than 24 hours; 3. Patients with a clinical diagnosis of hypoactive delirium.

Design outcomes

Primary

MeasureTime frame
Evaluate possible differences in duration of delirium between patients receiving either anti-psychotics + melatonin or anti-psychotics + placebo.

Secondary

MeasureTime frame
1. Evaluate possible differences in severity of delirium between the anti-psychotics + melatonin group and the anti-psychotics + placebo group; 2. Compare possible differences in the length of hospital stay in delirious patients in the anti-psychotic + melatonin group or anti-psychotic + placebo group; 3. Evaluate possible differences in the total dose of additional benzodiazepines used to treat delirium in both the anti-psychotics + melatonin group and the anti-psychotics + placebo group; 4. Evaluate possible differences in the total dose of haloperidol used during the period of delirium in the anti-psychotics + melatonin group and the anti-psychotics + placebo group; 5. Evaluate the possible effects of delirium and of melatonin therapy on cognitive function 3 months and 12 months after hospital admission; 6. Evaluate possible effects of delirium and of melatonin therapy on functional decline, measured by grip-strength and by KATZ questionnaire.

Contacts

Public ContactS.E. Rooij, de

Academic Medical Centre Amsterdam Internal-Geriatric Department Academic Medical Center Meibergdreef 9

(31)205669325

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)